Aardvark Therapeutics, Inc. AARD
5.06
(0.49)
(8.83%)
as of 25 Sep
- Market cap
- $121.5M
- P/E
- 0.0×
Follow AARD
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
12.03 | 10.61 | 8.06 | 12.63 |
Net Debt/EBITDA |
6.99 | 5.81 | 4.04 | 4.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.96 | 0.87 | 1.22 | |
Capex/Depreciation |
0.01 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.74) | (0.86) | (0.86) | (0.81) | |
Cash per Share |
5.82 | 5.61 | 4.18 | 3.38 | |
Shareholders Equity per Share |
5.64 | 5.43 | 3.99 | 3.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.64 | 5.43 | 3.99 | 3.42 | |
Free Cash Flow |
(16.13) | (16.81) | (18.87) | (17.60) | |
Working Capital |
118.47 | 101.34 | 81.98 | 74.27 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
118.36 | 101.34 | 81.98 | 74.00 | |
| Other line items | |||||
Quick Ratio |
11.77 | 10.43 | 7.86 | 11.57 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.74) | (0.86) | (0.86) | (0.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.74 | 2.19 | 3.52 | 3.57 | |
Average Assets |
66.61 | 97.34 | 127.81 | 114.47 | |
Average Common Equity |
43.79 | 26.00 | 118.84 | 105.86 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates